MetVital is developing a metabolic treatment that reduces free glutamate levels in the central nervous system using "Anhydrous Enol-Oxaloacetate" (AEO) a new thermally stable composition of matter oral medication that modifies metabolism. Free glutamate levels are reduced by as much as 40%, providing relief from excitotoxicity. This may benefit several diseases. MetVital's development pipeline for AEO has benefited from University studies including a Phase 1 and Phase 2 clinical trial in Alzheimer's Disease, a Phase 1 clinical trial in Amyotrophic Lateral Sclerosis (ALS), and is now moving forward with a commercial Phase 2A proof of concept trial in Glioblastoma Multiforme (GBM). MetVital is seeking both strategic partners and investment capital.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):